Skip to main content
Fig. 3 | BMC Immunology

Fig. 3

From: The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer

Fig. 3

Tumor growth in T cell-deficient mice is not affected by guadecitabine. 4 T1 tumor challenge in athymic mice, showing a tumor growth curve and b final excised tumor volume at day 16. Total cellularity and number of MDSCs from c spleen, d bone marrow, and e blood. f Representative images of day 16 frozen tumor sections stained with TUNEL for apoptotic cells in T cell-deficient control mice or mice treated with guadecitabine, showing no clear difference in degree of apoptosis. Dotted line indicates naïve levels. Significance determined by unpaired student’s T-test. Error bars represent SD. ns = not significant; *:p value< 0.0332; **:p value< 0.0021; ***:p value< 0.0002; ****:p value< 0.00001

Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us